Recognition of a New Chemotherapeutic Vesicant: Trabectedin (Ecteinascidin-743) Extravasation With Skin and Soft Tissue Damage
- 20 November 2009
- journal article
- case report
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 27 (33), e198-e200
- https://doi.org/10.1200/jco.2008.21.6473
Abstract
No abstract availableThis publication has 18 references indexed in Scilit:
- Phase II randomized study of trabectedin given as two different every 3 weeks dose schedules (1.5 mg/m2 24 h or 1.3 mg/m2 3 h) to patients with relapsed, platinum-sensitive, advanced ovarian cancerAnnals of Oncology, 2009
- Fatal rhabdomyolysis as a complication of ET-743 (Yondelis) chemotherapy for sarcoma: Case report and literature reviewCancer Biology & Therapy, 2007
- A phase II study of Yondelis® (trabectedin, ET-743) as a 24-h continuous intravenous infusion in pretreated advanced breast cancerBritish Journal of Cancer, 2006
- Phase II Study of ET-743 in Advanced Soft Tissue Sarcomas: A European Organisation for the Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group TrialJournal of Clinical Oncology, 2005
- Phase II Study of Ecteinascidin-743 in Advanced Pretreated Soft Tissue Sarcoma PatientsJournal of Clinical Oncology, 2004
- Rituximab therapy for indolent non-Hodgkinʼs IymphomaAnti-Cancer Drugs, 2002
- Retrospective Study of the Management of Chemotherapeutic Extravasation InjuryAnnals of Plastic Surgery, 2002
- Ecteinascidin-743 (ET-743), a natural marine compound, with a unique mechanism of actionEuropean Journal of Cancer, 2001
- Ecteinascidin 743: A Minor Groove Alkylator That Bends DNA toward the Major GrooveJournal of Medicinal Chemistry, 1999
- What Is the Appropriate Management of Tissue Extravasation by Antitumor Agents?Plastic and Reconstructive Surgery, 1985